Related by context. All words. (Click for frequent words.) 77 NSCLC 70 Cell Lung Cancer 69 metastatic colorectal cancer 68 advanced NSCLC 67 metastatic breast cancer 66 non squamous 65 metastatic renal cell carcinoma 65 lung cancers 65 metastatic breast 64 renal cell carcinoma 63 metastatic melanoma 63 metastatic 63 hormone refractory prostate cancer 63 HER2 positive 62 metastatic prostate cancer 62 cell carcinoma 62 HER2 positive breast cancer 61 hepatocellular cancer 61 unresectable 61 metastatic RCC 61 CLL 60 recurrent NSCLC 60 multiple myeloma 60 solid tumors 60 bladder cancers 59 metastatic pancreatic cancer 59 erlotinib 59 colorectal cancer 59 chronic lymphocytic leukemia CLL 59 resistant ovarian cancer 59 cancers 59 neuroendocrine tumors 59 adenocarcinoma 59 nonsmall cell lung cancer 59 gastrointestinal stromal tumor GIST 59 cutaneous T cell 59 HER2 positive metastatic breast 59 platinum refractory 59 malignant pleural mesothelioma 59 metastatic colorectal 59 brain metastases 59 liver metastases 58 sorafenib 58 Amrubicin 58 metastatic disease 58 lung malignant melanoma 58 pancreatic cancers 58 unresectable stage 58 prostate cancers 58 HNSCC 58 hepatocellular carcinoma HCC 58 non squamous NSCLC 58 soft tissue sarcomas 58 carcinoma 58 stage IIIB IV 58 mRCC 58 pancreatic carcinoma 58 axitinib 58 hematologic malignancies 58 follicular lymphoma 58 gefitinib 58 basal cell carcinoma BCC 58 stage IIIB 58 gemcitabine 58 docetaxel 58 soft tissue sarcoma 57 medullary thyroid cancer 57 HRPC 57 metastatic NSCLC 57 gastric cancer 57 refractory multiple myeloma 57 tumors GIST 57 lymphoma CTCL 57 bevacizumab 57 stage IIIb IV 57 malignancies 57 unresectable locally advanced 57 pancreatic adenocarcinoma 57 colorectal 57 indolent NHL 57 IV melanoma 57 prostate cancer CRPC 57 vandetanib 57 lung tumors 57 squamous non 57 phase IIb clinical 57 squamous cell 57 cetuximab 57 lung carcinoma 56 pancreatic NET 56 breast tumors 56 carfilzomib 56 idiopathic pulmonary fibrosis IPF 56 Vectibix 56 ovarian cancers 56 ASA# 56 tumors 56 glioblastoma multiforme GBM 56 glioblastoma 56 cisplatin 56 olaparib 56 metastatic cancer 56 hepatocellular carcinoma 56 gefitinib Iressa 56 lung ovarian 56 mCRC 56 metastatic cancers 56 lung carcinomas 56 carboplatin paclitaxel 56 lung pancreatic 56 gastrointestinal stromal tumors 56 vinorelbine 56 gastrointestinal stromal tumors GIST 56 relapsed ovarian cancer 56 castration resistant prostate cancer 55 B CLL 55 cetuximab Erbitux 55 chemotherapy regimens 55 IV metastatic melanoma 55 metastatic carcinoma 55 colorectal cancers 55 hematological malignancies 55 neuroendocrine cancers 55 cell lymphoma CTCL 55 Tarceva 55 lung cancer 55 recurrent ovarian cancer 55 IV NSCLC 55 pancreatic gastric 55 metastatic colon cancer 55 castrate resistant prostate cancer 55 chemoradiation 55 temsirolimus 55 recurrent colorectal cancer 55 serous ovarian cancer 55 colorectal cancer CRC 55 pancreatic neuroendocrine tumors 55 HGS ETR1 55 docetaxel Taxotere R 55 metastatic renal cell 55 advanced unresectable 55 gastrointestinal cancers 55 heavily pretreated 55 IMGN# 55 DLBCL 54 seminoma 54 Nexavar 54 paclitaxel carboplatin 54 lymphoma 54 gastric cancers 54 relapsed SCLC 54 metastatic hormone refractory 54 myelodysplastic syndrome MDS 54 picoplatin 54 squamous cell carcinoma 54 ovarian cancer 54 breast cancers 54 chemoradiotherapy 54 Hepatocellular Carcinoma HCC 54 trabectedin 54 glufosfamide 54 melanoma 54 breast pancreatic 54 Metastatic 54 metastatic lung cancer 54 acute myelogenous leukemia AML 54 prostate cancer HRPC 54 taxane therapy 54 invasive bladder 54 resectable 54 cancer mCRC 54 leukemia AML 54 nab paclitaxel 54 lymphomas 54 sunitinib 54 recurrent metastatic 54 carboplatin 54 lung adenocarcinoma 54 recurrent glioblastoma 54 hematological cancers 54 squamous cell cancer 54 histologies 54 grade gliomas 54 capecitabine 54 sarcoma 54 erlotinib Tarceva ® 54 breast ovarian 54 plus gemcitabine 54 relapsed refractory multiple myeloma 54 metastatic malignant melanoma 54 Nexavar sorafenib 54 HER2 negative 54 Targretin 54 nonsquamous histology 54 superficial bladder cancer 54 differentiated thyroid 54 obatoclax 53 peritoneal carcinomatosis 53 taxane 53 Genasense ® 53 lung colorectal 53 metastatic castrate resistant 53 bevacizumab Avastin 53 AP# [003] 53 advanced hepatocellular carcinoma 53 lung cancer NSCLC 53 medically inoperable 53 lapatinib 53 Erlotinib 53 OPAXIO 53 bortezomib 53 carcinoid tumors 53 diabetic nephropathy 53 Proxinium TM 53 trastuzumab DM1 T DM1 53 Tarceva erlotinib 53 satraplatin 53 gemcitabine chemotherapy 53 Erbitux 53 adjuvant therapy 53 irinotecan chemotherapy 53 ZACTIMA 53 metastatic bladder 53 pemetrexed 53 Erbitux cetuximab 53 MAGE A3 53 Cloretazine ® 53 squamous cell histology 53 squamous 53 refractory CLL 53 Taxotere ® 53 carcinomas 53 KRAS wild 53 metastatic gastric 53 HER2 + 53 L BLP# 53 FOLOTYN 53 locoregional 53 relapsed refractory 53 malignant melanoma 53 Cloretazine 53 palifosfamide 53 temozolomide 53 IV malignant melanoma 53 liver cancer 53 advanced metastatic renal 53 Hycamtin 53 sunitinib malate 53 distant metastasis 53 OncoVEX GM CSF 53 Allovectin 7 53 refractory metastatic colorectal cancer 53 cell carcinomas 53 amrubicin 53 CTCL 53 Surgical resection 53 IgG1 monoclonal antibody 53 neoadjuvant therapy 53 carcinoid 53 GIST 53 mapatumumab 53 HRPC ovarian cancer 53 multiple myeloma MM 53 fluoropyrimidine 53 EGFR mutation positive 52 recurrent GBM 52 BR.# 52 refractory CTCL 52 imetelstat 52 localized prostate cancer 52 Folotyn 52 randomized Phase 52 docetaxel Taxotere ® 52 cintredekin besudotox 52 neoadjuvant chemotherapy 52 glioblastomas 52 angiogenesis inhibitor 52 biliary tract cancer 52 XL# [003] 52 Avastin 52 cytotoxic chemotherapy 52 bevacizumab Avastin ® 52 Sutent 52 abiraterone 52 FOLFOX6 52 elacytarabine 52 acute myeloid leukemia AML 52 Docetaxel 52 Phase III clinical 52 leukemia CLL 52 tumor recurrence 52 relapsed multiple myeloma 52 prostate carcinoma 52 refractory AML 52 IMC A# 52 monotherapy 52 tesmilifene 52 bone metastasis 52 cisplatin chemotherapy 52 cutaneous T 52 perifosine 52 histone deacetylase HDAC inhibitor 52 Gefitinib 52 chemotherapy regimen 52 YONDELIS 52 colon cancer 52 cell lymphoma 52 dasatinib Sprycel 52 sapacitabine 52 alvespimycin 52 Irinotecan 52 lupus nephritis 52 BRIM3 52 SCCHN 52 crizotinib 52 Doxil ® 52 Zybrestat 52 hematologic disorders 52 CYT# potent vascular disrupting 52 follicular non 52 Taxotere 52 EGFR mutation 52 chronic myeloid leukemia CML 52 EGFR tyrosine kinase inhibitors 52 sorafenib Nexavar 52 Metastatic breast cancer 52 figitumumab 52 gastrointestinal stromal tumor 52 AQ4N 52 afatinib 52 dasatinib 52 Perifosine 52 metastatic GIST 52 anti leukemic 52 recurrent glioblastoma multiforme 52 iniparib 52 SCH # 52 docetaxel chemotherapy 52 FOLFIRI 52 ovarian lung 52 BAY #-# 52 T DM1 52 squamous cell lung cancer 52 basal cell carcinomas 52 standard chemotherapy regimen 52 pancreatic cancer 52 alkylating agent 52 AA amyloidosis 52 ZYBRESTAT 52 lung adenocarcinomas 52 sorafenib Nexavar ® 51 systemic ALCL 51 tivozanib 51 Torisel 51 metastatic kidney 51 cell lymphoma DLBCL 51 antibody MAb 51 sarcomas 51 Fludara 51 breast carcinomas 51 Taxotere R 51 metastatic squamous cell carcinoma 51 TNFerade 51 Pemetrexed 51 colorectal lung 51 pegylated liposomal doxorubicin 51 HCV infection 51 anthracyclines 51 stage IIIA 51 pomalidomide 51 Gleevec resistant 51 antitumor activity 51 nasopharyngeal cancer 51 tesetaxel 51 seliciclib 51 androgen independent 51 mutated KRAS gene 51 sorafenib tablets 51 AEG# 51 ovarian breast 51 non Hodgkin lymphoma 51 chronic lymphocytic leukemia 51 chlorambucil 51 colorectal carcinoma 51 lintuzumab 51 EGFR mutations 51 doublet chemotherapy 51 lymphocytic leukemia 51 IRESSA 51 registrational 51 cediranib 51 tyrosine kinase inhibitors 51 Ceflatonin 51 cutaneous melanoma 51 metastatic liver 51 EGFR expressing 51 mCRC patients 51 Nexavar tablets 51 Amigal 51 SIR Spheres 51 cystic fibrosis bronchiectasis 51 Phase Ib clinical trials 51 pertuzumab 51 prostate cancer AIPC 51 Ixempra 51 completely resected 51 metastatic HRPC 51 heavily pretreated patients 51 Zolinza 51 PLX# 51 grade glioma 51 adenocarcinomas 51 TheraSphere 51 pazopanib 51 enzastaurin 51 Azixa 51 hepatitis C HCV 51 TORISEL 51 non resectable 51 myelofibrosis 51 colon cancers 51 epithelial tumors 51 receptor tyrosine kinase inhibitor 51 acute myeloid leukemia 51 Sorafenib 51 pralatrexate 51 myelodysplastic syndromes 51 phase IIb trial 51 chemotherapeutic agents 51 forodesine 51 prostate cancer 51 diagnosed multiple myeloma 51 imatinib Gleevec ® 51 Renal cell carcinoma 51 adjuvant chemotherapy 51 vemurafenib 51 metastases 51 epithelial ovarian cancer 51 lung prostate 51 EGFR TKI 51 fallopian tube carcinoma 51 HBeAg negative 51 PARP inhibitor 51 IRX 2 51 Xyotax 51 PKCi 51 Advexin 51 invasive candidiasis 51 Paraplatin ® carboplatin 51 trastuzumab 51 squamous histology 51 colorectal tumors 51 follicular lymphoma FL 51 panitumumab Vectibix 51 pancreatic tumors 51 evaluating picoplatin 51 KRAS mutation 51 endometrial cancers 51 BRAF inhibitor 51 cytotoxic therapy 51 peritoneal cancer 51 refractory chronic lymphocytic 51 refractory PTCL 51 aflibercept 51 hormone receptor positive 51 Hodgkin lymphoma NHL 51 Tamibarotene 51 Acute Myelogenous Leukemia AML 51 biologic therapy 51 SUTENT 51 Gemzar ® 51 TTF Therapy 51 skeletal metastases 50 dacarbazine 50 xenograft models 50 topotecan 50 trastuzumab DM1 50 Atiprimod 50 gemcitabine Gemzar 50 disease progression 50 Xeloda 50 imatinib resistant 50 pancreatic ovarian 50 entinostat 50 zalutumumab 50 GISTs 50 oral ridaforolimus 50 vismodegib 50 ADVEXIN 50 aflibercept VEGF Trap 50 Insegia 50 premalignant lesions 50 liposomal doxorubicin 50 myeloma 50 panitumumab 50 basal cell carcinoma 50 Folfox 50 docetaxel Taxotere 50 oropharyngeal cancer 50 bendamustine 50 mycosis fungoides 50 ELOXATIN 50 multi kinase inhibitor 50 Alessandro Riva 50 myelofibrosis polycythemia vera 50 CINTREDEKIN BESUDOTOX 50 abiraterone acetate 50 PXD# 50 Satraplatin 50 taxanes 50 BRIM2 50 irinotecan 50 trastuzumab Herceptin ® 50 clinical trial 50 papillary renal cell carcinoma 50 prostate cancer mCRPC 50 Adjuvant chemotherapy 50 Vicinium TM 50 clinical trials 50 eribulin 50 talactoferrin 50 Lung transplantation 50 vinca alkaloid 50 pegylated interferon alpha 50 5 fluorouracil 50 cetuximab Erbitux ® 50 pegylated interferon 50 malignant growths 50 ELACYT 50 chemotherapeutic agent 50 TTR amyloidosis 50 relapsing remitting multiple sclerosis 50 Stage IIIb 50 depsipeptide 50 phase IIb study 50 Gemcitabine 50 IIIB NSCLC 50 sunitinib Sutent 50 pleural mesothelioma 50 Phase 2b clinical 50 familial amyloidotic polyneuropathy FAP 50 LUX Lung 50 vascular disrupting agent 50 palliative radiotherapy 50 Alemtuzumab 50 pheochromocytoma 50 BRCA deficient 50 colorectal breast 50 tumor shrinkage 50 FOLFOX 50 Evoltra ® 50 refractory prostate cancer 50 randomized Phase III 50 melanomas 50 rituximab 50 recurrent malignant glioma 50 metastatic relapsed 50 Glioblastoma Multiforme GBM 50 nodular BCC 50 metastatic HER2 positive 50 PARP inhibitors 50 huC# DM4 50 tumor progression 50 neoadjuvant treatment 50 unresectable liver cancer 50 transthyretin amyloidosis 50 non alcoholic steatohepatitis 50 leukemia APL 50 proliferative diabetic retinopathy 50 Follicular lymphoma 50 pancreatic prostate 50 multicenter Phase II 50 neck squamous cell 50 Acute Myeloid Leukemia AML 50 subependymal giant cell 50 antibiotic anti infective 50 PSMA ADC 50 carcinoma HCC 50 Halaven 50 bladder cancer 50 IL# PE#QQR 50 cisplatin resistant 50 ticagrelor 50 Cloretazine R 50 PDX pralatrexate 50 decitabine 50 lung metastases 50 Mantle Cell Lymphoma 50 nonmetastatic 50 cell lymphomas 50 imatinib Gleevec 50 SBRT 50 Glioblastoma multiforme 50 adecatumumab 50 operable breast cancer 50 ongoing Phase 1b 50 ganetespib 50 MyVax R 50 Afatinib 50 neoplasia 50 refractory Hodgkin lymphoma 50 CLL SLL 50 astrocytoma 50 tumor 50 Afinitor 50 cell lymphoma ALCL 50 CANCIDAS 50 dacarbazine chemotherapy 50 unresectable Stage III 50 samalizumab 50 malignant lymphoma 50 Kit CD# positive 50 gastroesophageal junction 50 grade cervical intraepithelial 50 BRAF V# mutation 50 Phase 2b study 50 Theratope 50 metastatic HER2 negative 50 ixabepilone 50 myelodysplastic syndromes MDS 50 cell carcinoma RCC 50 cabazitaxel 50 standard chemotherapy regimens 50 stage IIIb 50 adjuvant radiation 50 Taxotere docetaxel 49 VIDAZA 49 micafungin 49 pancreatic colorectal 49 Renal Cell Carcinoma RCC 49 haematological malignancies 49 CR# vcMMAE 49 trastuzumab Herceptin R 49 Xanafide 49 HER2 positive cancers 49 gemcitabine carboplatin 49 dirucotide 49 novel histone deacetylase 49 refractory NSCLC 49 KRAS mutations occur 49 curable cancers 49 Phase Ib clinical 49 darapladib 49 CHOP chemotherapy 49 kinase inhibitor 49 eribulin mesylate 49 colorectal liver metastases 49 Tavocept 49 KRAS mutant tumors 49 FOLFOX chemotherapy 49 cilengitide 49 pan HDAC inhibitor 49 PROVENGE 49 LBH# 49 metastatic colorectal carcinoma 49 renal tumors 49 dasatinib Sprycel ® 49 anthracycline containing 49 liver metastasis 49 pancreatic 49 Phase 2b trial 49 Apaziquone 49 Pixantrone 49 AVASTIN 49 Medullary thyroid cancer 49 oncological indications 49 Allovectin 7 ® 49 EGFR inhibitors 49 Alimta 49 ERBITUX 49 BRCA mutation carriers 49 lymph node metastases 49 Velcade bortezomib 49 bone metastases 49 LEP ETU 49 anti angiogenic therapy 49 follicular NHL 49 metastatic pancreatic 49 paclitaxel 49 tanespimycin 49 metastatic malignant 49 TREANDA 49 Vandetanib 49 ThermoDox R 49 Metastatic Colorectal Cancer 49 BLP# Liposome Vaccine 49 investigational compound 49 liposomal amphotericin B 49 melanoma skin 49 radiation sensitizer 49 acute leukemias 49 EOquin TM 49 DMARD 49 Ozarelix 49 Canvaxin 49 Tykerb 49 carcinoid cancer 49 squamous cell carcinoma SCC 49 Jevtana 49 leukaemias 49 taxane chemotherapy 49 breast carcinoma 49 thymoma 49 biliary cancer 49 systemic lupus erythematosus SLE 49 refractory indolent non 49 CA4P 49 metastatic ovarian cancer 49 opioid induced constipation OIC 49 Cetuximab Erbitux 49 Phase Ib 49 relapsed leukemia 49 anticancer compound 49 ipilimumab 49 ovarian carcinoma 49 OMAPRO 49 Merck KGaA Erbitux 49 nonsquamous 49 DCVax R Brain 49 MAGE A3 ASCI 49 refractory APL 49 advanced adenomas 49 urothelial bladder cancer 49 investigational monoclonal antibody 49 ISEL 49 belinostat 49 KRAS mutant 49 Seliciclib 49 neoadjuvant 49 Stage IIIb IV 49 candidemia 49 pivotal Phase 49 Pirfenidone 49 chemoresistant 49 bladder ovarian 49 radiofrequency ablation RFA 49 CoFactor 49 antitumor effect 49 clinically localized prostate 49 anthracycline taxane 49 Aflibercept 49 Virulizin ® 49 ductal adenocarcinoma 49 remission induction 49 cangrelor 49 recurrent squamous cell carcinoma 49 chemotherapy cisplatin 49 evaluating tivozanib 49 Cloretazine R VNP#M 49 Phenoptin 49 resistant hormone refractory 49 vinflunine 49 symptomatic BPH 49 NSCLC tumors 49 refractory acute myeloid 49 BEXXAR 49 Bezielle 49 Lapatinib 49 chronic myeloid 49 XELOX 49 5-FU/LV 49 leukemia ALL 49 HGS# 49 Romidepsin 49 chemotherapy 49 metastatic medullary thyroid 49 OvaRex ® MAb 49 monoclonal antibody conjugated 49 talabostat 49 rectal cancers 49 Sutent sunitinib 49 EpCAM 49 ABRAXANE 49 FOLFOX4 49 Avastin bevacizumab 49 premalignant 49 acute myelogenous leukemia 49 chronic myelogenous leukemia CML 49 lung nodules 49 HER2 49 EOquin 49 imatinib 49 pirfenidone 49 GRN#L 49 prostate tumors 49 phase Ib 49 protease inhibitor PI 49 ALCL 49 Nimotuzumab 49 thalidomide Thalomid 49 Exherin TM 49 Iressa 49 vinca alkaloids 49 malignancy 49 T#I [002] 48 Tarceva TM 48 Idiopathic Pulmonary Fibrosis 48 phase IIb 48 lymphoma subtypes 48 Carcinoma 48 FOLFOX regimen 48 IMC #B 48 haematologic malignancies 48 atypical Hemolytic Uremic Syndrome 48 tumor subtypes 48 small lymphocytic lymphoma 48 MDV# 48 EGFR expressing mCRC 48 Phase #b/#a clinical 48 pain palliation 48 MPS IVA 48 Glioblastoma 48 Rituxan rituximab 48 BCIRG 48 EFAPROXYN 48 investigational immunotherapy 48 PROSTVAC ® 48 ErbB2 positive 48 refractory colorectal cancer 48 TELINTRA 48 INCB# [001] 48 squamous cell carcinomas 48 Yondelis 48 non metastatic osteosarcoma 48 Abraxane 48 immunotherapeutic agent 48 Axitinib 48 pulmonary arterial hypertension 48 histone deacetylase inhibitor 48 prostate cancer PCa 48 minimally symptomatic 48 nonmelanoma skin cancers 48 endometrial cancer 48 MEK inhibitors 48 Motesanib 48 Fludara ® 48 TG# [001] 48 imetelstat GRN#L 48 Telcyta 48 Alpharadin 48 RNAi therapeutic targeting 48 microsphere therapy 48 oritavancin 48 IMA# 48 nimotuzumab 48 Asentar 48 metastatic CRC 48 ZADAXIN ® 48 VNP#M 48 fludarabine 48 RG# [001] 48 chronic hepatitis C 48 Selective Internal 48 Carfilzomib 48 Cytoxan 48 prostate cancer CaP 48 leiomyosarcoma 48 relapsed CLL 48 colon esophageal 48 Annamycin 48 sodium thiosulfate STS 48 phenoxodiol 48 GVAX 48 HuMax EGFr 48 MALT lymphoma 48 NMIBC 48 regorafenib 48 valopicitabine 48 anti EGFR antibody 48 Glioblastoma Multiforme 48 cytotoxic 48 Pegasys ® 48 Epratuzumab 48 radiolabeled TM# 48 MGCD# [002] 48 GvHD 48 refractory chronic myeloid 48 eosinophilic asthma 48 Phase III clinical trials 48 chemotherapeutic regimen 48 Actemra 48 HGS ETR1 mapatumumab 48 Radiation Therapy SIRT 48 chemotherapeutic 48 FOLOTYN ® 48 Stimuvax 48 LHRH receptor positive 48 Chronic lymphocytic leukemia 48 invasive lobular carcinoma 48 Herceptin trastuzumab 48 mycophenolate mofetil 48 cancerous enlargement 48 COU AA 48 Toxicities 48 apaziquone 48 cytokine refractory 48 OXi# 48 Gorlin syndrome 48 proteasome inhibitor 48 Genasense 48 colorectal pancreatic 48 capecitabine Xeloda 48 daclizumab 48 refractory ovarian cancer 48 lumiliximab 48 Xeloda capecitabine 48 acyclovir Lauriad R 48 anaplastic thyroid carcinoma 48 REVLIMID 48 calcium phosphate binder 48 Aplidin 48 Hodgkin lymphomas 48 lenalidomide Revlimid R 48 fluorouracil 48 XYOTAX 48 malignant polyps 48 Troxatyl 48 PEP# [003] 48 infantile onset 48 renal carcinoma 48 castrate resistant 48 chronic HCV 48 gastric carcinoma 48 assessing T DM1 48 PANVAC VF 48 thymalfasin 48 Peginterferon alfa 2b 48 huN# DM1 48 microtubule inhibitor 48 advanced epithelial ovarian 48 Prostate cancer 48 cholangiocarcinoma 48 GLP toxicology studies 48 malignant pheochromocytoma 48 metastatic castration resistant 48 actinic keratosis 48 systemic fungal infections 48 Li Fraumeni Syndrome 48 paclitaxel Taxol ® 48 Brain metastases 48 PNP inhibitor 48 metastatic tumors 48 Barrett esophagus 48 colorectal ovarian 48 Xcytrin 48 NovoTTF 48 mutated KRAS 48 nucleoside 48 neratinib 48 Chronic Lymphocytic Leukemia 48 panobinostat 48 TEMODAL 48 pivotal Phase III 48 lymph node involvement 48 refractory metastatic 48 interferon alfa 48 metastatic lesions 48 ToGA 48 Phase 1b 48 esophageal cancers 48 cardiotoxicity 48 allergic asthma 48 oncology indications 48 heterozygous FH 48 Uricase PEG 48 tumor xenograft models 48 registrational trial 48 Azedra 48 prostate tumor 48 Cimzia TM 48 Alimta pemetrexed 48 interferon ribavirin 48 5 FU leucovorin 48 ADVEXIN therapy 48 Cutaneous T 48 dose escalation study 48 ovarian pancreatic 48 LE DT 48 recurrent glioblastoma multiforme GBM 48 Non Hodgkin lymphoma 48 VFEND 48 Lung cancer 48 relapsing remitting 48 gemcitabine Gemzar ® 48 HCV infections 48 Xelox 48 locoregional recurrence 48 luteinizing hormone releasing 48 Phase Ib II 48 SJIA 48 paraganglioma 48 Quinamed 48 Clolar 48 nasopharyngeal carcinoma 48 rituximab Rituxan 48 lorvotuzumab mertansine 48 tyrosine kinase inhibitor 48 Duchenne muscular dystrophy DMD 48 ACTEMRA TM